Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Aclaris Therapeutics和其他一只低于5美元的股票内部人士正在购买
The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周五收盘上涨约0.2％。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是细价股最近几笔值得注意的内幕交易。欲了解更多信息，请访问Benzinga的内幕交易平台。
Aclaris Therapeutics
Aclaris 疗法
- The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 352,397 shares at an average price of $1.15. To acquire these shares, it cost around $405,894.
- What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
- What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.
- 交易：Aclaris Therapeutics, Inc.（纳斯达克股票代码：ACRS）10％的所有者布雷登·迈克尔·伦纳德共购买了352,397股股票，平均价格为1.15美元。收购这些股票的成本约为405,894美元。
- 发生了什么：5月7日，Aclaris Therapeutics公布了乐观的季度业绩。
- Aclaris Therapeutics的所作所为：Aclaris Therapeutics Inc是一家临床阶段的生物制药公司，在美国运营。
RENN Fund
RENN 基金
- The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 184 shares at an average price of $1.74. To acquire these shares, it cost around $320.
- What's Happening: RENN Fund shares rose around 5% over the past month.
- What RENN Fund Does: RENN Fund Inc is active in the financial services domain.
- 交易：RENN基金公司（纽约证券交易所代码：RCG）总裁兼首席执行官默里·斯塔尔共收购了184股股票，平均价格为1.74美元。收购这些股票的成本约为320美元。
- 发生了什么：RENN基金的股价在过去一个月中上涨了约5％。
- RENN基金的作用：RENN基金公司活跃于金融服务领域。